These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 24705344

  • 1. Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.
    Cox MC, Di Napoli A, Scarpino S, Salerno G, Tatarelli C, Talerico C, Lombardi M, Monarca B, Amadori S, Ruco L.
    PLoS One; 2014; 9(4):e93903. PubMed ID: 24705344
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z, Niu J, Cao Y, Pang X, Cui W, Zhang W, Li X.
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N, Uner A, Benekli M, Barista I.
    Cancer; 2012 Sep 01; 118(17):4173-83. PubMed ID: 22213394
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group.
    Blood; 2013 Mar 21; 121(12):2253-63. PubMed ID: 23335369
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C, Li W, Liu C, He H, Bai O.
    Blood Cells Mol Dis; 2016 Mar 21; 57():42-9. PubMed ID: 26852654
    [Abstract] [Full Text] [Related]

  • 12. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ, Gang AO, Brown P, Pedersen M, Knudsen H, Nielsen SL, Poulsen T, Wirenfeldt Klausen T, Høgdall E, Nørgaard P.
    PLoS One; 2017 Mar 21; 12(10):e0186983. PubMed ID: 29088292
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
    Gong QX, Lu TX, Liu C, Wang Z, Liang JH, Xu W, Li JY, Zhang ZH, Chen Q.
    Int J Clin Exp Pathol; 2015 Mar 21; 8(12):15825-35. PubMed ID: 26884853
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
    Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD.
    J Clin Oncol; 2015 Sep 10; 33(26):2848-56. PubMed ID: 26240231
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
    Suzuki T, Maruyama D, Miyagi-Maeshima A, Nomoto J, Tajima K, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Taniguchi H, Izutsu K, Kobayashi Y, Tobinai K.
    Cancer Med; 2021 Aug 10; 10(15):5101-5109. PubMed ID: 34105893
    [Abstract] [Full Text] [Related]

  • 17. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH.
    Haematologica; 2013 Feb 10; 98(2):255-63. PubMed ID: 22929980
    [Abstract] [Full Text] [Related]

  • 18. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M, Laszlo S, Triumf J, Hedström G, Berglund M, Enblad G, Amini RM.
    Acta Oncol; 2016 Feb 10; 55(9-10):1126-1131. PubMed ID: 27549735
    [Abstract] [Full Text] [Related]

  • 19. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R.
    Curr Treat Options Oncol; 2018 Sep 10; 19(11):52. PubMed ID: 30203318
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.
    Oncotarget; 2016 Jan 19; 7(3):2401-16. PubMed ID: 26573234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.